# Computationally Guided Structural Modification of Centaureidin: A Novel Approach for Enhancing Antioxidant and Antitumor Activities for Drug Development

**Authors:** Reem S. Alruhaimi, Emadeldin M. Kamel, Sulaiman M. Alnasser, Ibrahim Elbagory, Ayman M. Mahmoud, Al Mokhtar Lamsabhi

PMC · DOI: 10.1111/cbdd.70149 · 2025-07-03

## TL;DR

Researchers used computational methods to modify a natural compound, centaureidin, to improve its antioxidant and cancer-fighting properties, creating a promising new drug candidate.

## Contribution

A novel computational and experimental approach to enhance the therapeutic potential of centaureidin through structural modification.

## Key findings

- CA1 and CA4 analogues showed stronger radical scavenging activity than centaureidin.
- Both analogues inhibited MCF-7 cancer cell proliferation more effectively.
- Modified compounds exhibited strong binding affinity to key cancer-related proteins.

## Abstract

The development of novel therapeutic drugs with enhanced efficacy has gained significant attention in recent years. In this study, we aimed to enhance the radical scavenging and antitumor activities of centaureidin through computationally guided structural modifications. Centaureidin was initially isolated through extensive phytochemical fractionation from Centaurea scoparia. We employed Density Functional Theory (DFT) and multitarget molecular modeling to explore how modifying the carbon‐8 (C‐8) position influences bond dissociation enthalpies, radical scavenging mechanisms, and the structure‐antitumor activity relationships. Guided by computational analysis, we then modified the core skeleton of centaureidin using a facile multicomponent Mannich‐type synthesis, resulting in two newly substituted centaureidin analogues. The radical scavenging properties of centaureidin and its analogues CA1 and CA4 were investigated using DPPH and ABTS assays. CA1 and CA4 revealed more potent radical scavenging activities. In addition, both analogues were more effective in inhibiting the proliferation of the MCF‐7 cancer cell line. All tested compounds exhibited binding affinity towards caspase‐3 and the receptors EGFR, HER2 and VEGFR. In conclusion, structural modification of centaureidin resulted in enhanced antioxidant and cytotoxic activities. This comprehensive approach offers a streamlined and cost‐effective pathway for drug design and development, providing valuable insights for researchers in the field of therapeutic drug production.

Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities. Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy.

## Linked entities

- **Proteins:** Casp3 (caspase 3), EGFR (epidermal growth factor receptor), ERBB2 (erb-b2 receptor tyrosine kinase 2), KDR (kinase insert domain receptor)
- **Chemicals:** centaureidin (PubChem CID 5315773), CA1 (PubChem CID 6481884), CA4 (PubChem CID 5351344), ABTS (PubChem CID 35688)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}
- **Diseases:** cancer (MESH:D009369), cytotoxic (MESH:D064420)
- **Chemicals:** C (MESH:D002244), Centaureidin (MESH:C083161), DPPH (MESH:C004931), CA1 (MESH:C063690), CA4 (MESH:C058728), ABTS (MESH:C002502)
- **Species:** Centaurea scoparia (species) [taxon 2072395]
- **Cell lines:** MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12231936/full.md

---
Source: https://tomesphere.com/paper/PMC12231936